Alaunos Therapeutics (TCRT) Shares Outstanding (Weighted Average) (2009 - 2026)

Alaunos Therapeutics has reported Shares Outstanding (Weighted Average) for 18 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 7237.89% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 7237.89% YoY), and the FY2025 full-year result was $1.9 million, up 21.68% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $1.9 million, up from $106452.0 in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $215.0 million in Q3 2022, with the low at $26552.0 in Q1 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $39.6 million across 5 years, with a median of $1.6 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) plunged 99.93% — and 2026, when it soared 7237.89%.
• Alaunos Therapeutics' Shares Outstanding (Weighted Average) stood at $145236.0 in 2022, then changed by 0.0% to $145236.0 in 2023, then soared by 1002.52% to $1.6 million in 2024, then plunged by 93.35% to $106452.0 in 2025, then surged by 1730.27% to $1.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $1.9 million (Q1 2026), $106452.0 (Q4 2025), and $168751.0 (Q3 2025), per Business Quant data.